Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Clear Secure Inc — how do they compare? Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B), while Clear Secure Inc trades at $43.42 (market cap $4.49B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 29.9× Clear Secure Inc's market cap, and Clear Secure Inc pays a 1.32% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| VRTX | YOU | |
|---|---|---|
Market Cap | $134.06B | $4.49B |
Sector | Health | Technology |
52-Week High | $557.96 | $62.36 |
52-Week Low | $376.62 | $29.61 |
Enterprise Value | $128.18B | $3.64B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Clear Secure (YOU) trades at $43.6, down 1.65% on the day, amid a bearish technical signal. The company shows strong fundamental momentum with 27% year-over-year revenue growth in Q2 2026 and expanding profitability, though valuation ratios like a P/E of 29.46 appear elevated. Recent news highlights a strategic partnership with CrowdStrike and the launch of corporate memberships, signaling growth initiatives beyond airports.
The outlook is mixed: robust earnings beats and membership growth support upside, but high valuation and insider selling pose risks. Analyst consensus is evenly split between Buy and Hold, reflecting cautious optimism. Key near-term catalysts include Q3 2026 earnings and the success of new enterprise offerings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
